Friday, September 10, 2021

Ayala Pharmaceuticals (AYLA)
Looking Forward To AL101 Data Presentation

Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company’s current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell specific leukemia.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

AL101 Data Expected Shortly.  Ayala plans to present data from AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, to be held September 16-September 21, 2021. The first presentation is from the Phase 2 ACCURACY clinical trial testing AL101 in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch-activating mutations. A second preclinical study testing AL101 as combination therapy for dual targeting of Notch dysregulated tumors will also be presented.


Data Presentation Is From The Second Dose Level.  The data will be from the second cohort in the ACCURACY trial that received the 6 mg dose. This cohort enrolled 42 patients with recurrent or metastatic adenoid cystic carcinoma (R/M ACC) and Notch-activating mutations. In September 2020, data from the first cohort of 45 patients receiving a 4mg dose of AL101 showed a disease control rate of 68% …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.